Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The endocannabinoid system (ECS) enzymes and transport machinery constitute the metabolic framework that regulates the levels of endogenous cannabinoids, such as anandamide (AEA) and 2-arachidonoylglycerol (2-AG) [1, 2]. This system includes degradative enzymes like Fatty Acid Amide Hydrolase (FAAH) and Monoacylglycerol Lipase (MAGL), as well as biosynthetic enzymes like N-acyl phosphatidylethanolamine-specific phospholipase D (NAPE-PLD) and diacylglycerol lipase (DAGL) [3, 4]. Additionally, transport mechanisms involving Fatty Acid Binding Proteins (FABPs) and putative membrane transporters facilitate the movement of these lipophilic ligands to their metabolic sites [5]. Pharmacological targeting of these enzymes, particularly FAAH and MAGL inhibitors, aims to elevate local endocannabinoid concentrations to provide analgesic, anti-inflammatory, and anxiolytic effects [6]. This approach is considered a promising therapeutic strategy for various conditions, including chronic pain, neurodegenerative diseases, and mood disorders, potentially offering a better safety profile than direct cannabinoid receptor agonists [7]. Citations: [1] Piomelli D. (2003). Nature Reviews Neuroscience. 4(11):873-884. [2] Fowler CJ. (2012). British Journal of Pharmacology. 166(5):1568-1585. [3] Ueda N, et al. (2013). Progress in Lipid Research. 52(4):427-435. [4] Bisogno T, et al. (2003). Journal of Cell Biology. 163(3):463-468. [5] Kaczocha M, et al. (2009). PNAS. 106(15):6375-6380. [6] Chicca A, et al. (2017). British Journal of Pharmacology. 174(14):2265-2281. [7] Di Marzo V. (2018). Nature Reviews Drug Discovery. 17(9):623-639.
Inhibition of endocannabinoid degradation and transport to increase endogenous ligand levels
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Endocannabinoid system enzymes and transport (ECS enzymes and transporters).